ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease
October 20, 2021Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in phase II trial for the treatment of thyroid eye disease (TED). -
FDA Advisory Committee votes unanimously to support use of teprotumumab to treat thyroid eye disease
December 20, 2019Horizon Therapeutics announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the US Food and Drug Administration (FDA) voted unanimously ...
Pharma Sources Insight January 2025
